Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Dual antiplatelet therapy (DAPT) is standard after percutaneous coronary intervention (PCI) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
• Early aspirin withdrawal, or P2Y12-inhibitor monotherapy, may reduce bleeding complications.
• The optimal timing for aspirin cessation post-PCI for NSTE-ACS remains unclear, especially in the initial high-risk period.

Purpose of the Study:

• To evaluate the safety and efficacy of immediate P2Y12-inhibitor monotherapy compared to DAPT in NSTE-ACS patients undergoing PCI.
• To determine if omitting aspirin immediately post-PCI reduces bleeding events without compromising ischemic outcomes.

Main Methods:

• An open-label, multicenter randomized controlled trial involving 3,090 patients.
• Patients were randomized immediately post-PCI to either 12 months of DAPT or P2Y12-inhibitor monotherapy (no aspirin).
• Primary endpoint: superiority in reducing major or minor bleeding (BARC 2, 3, or 5). Secondary endpoint: noninferiority for the composite of all-cause mortality, myocardial infarction, and stroke.

Main Results:

• The LEGACY study is the first randomized trial specifically designed to assess immediate aspirin omission post-PCI for NSTE-ACS.
• It compares P2Y12-inhibitor monotherapy against DAPT over 12 months.
• The study focuses on the balance between bleeding reduction and ischemic event prevention.

Conclusions:

• Immediate P2Y12-inhibitor monotherapy following PCI for NSTE-ACS is being investigated as a strategy to reduce bleeding.
• The LEGACY trial aims to establish whether this approach is a safe and effective alternative to standard DAPT.
• Findings will inform clinical practice regarding antiplatelet strategies post-PCI.